Chinook Therapeutics (NASDAQ:KDNY) issued its quarterly earnings data on Tuesday. The company reported ($1.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.82), MarketWatch Earnings reports. Chinook Therapeutics had a negative return on equity of 112.72% and a negative net margin of 215.80%.
Shares of NASDAQ KDNY opened at $14.75 on Thursday. Chinook Therapeutics has a twelve month low of $10.50 and a twelve month high of $21.68. The stock has a market cap of $621.83 million, a price-to-earnings ratio of -4.10 and a beta of 0.26. The stock has a 50 day moving average price of $16.88.
Several analysts have commented on KDNY shares. Bloom Burton restated a “buy” rating on shares of Chinook Therapeutics in a report on Monday, March 22nd. Zacks Investment Research upgraded shares of Chinook Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 11th. Cantor Fitzgerald assumed coverage on shares of Chinook Therapeutics in a report on Wednesday, December 9th. They set an “overweight” rating and a $31.00 target price for the company. Finally, Wedbush assumed coverage on shares of Chinook Therapeutics in a report on Wednesday, January 6th. They set an “outperform” rating and a $28.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Chinook Therapeutics currently has an average rating of “Buy” and an average target price of $28.29.
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.
Recommended Story: What is an inverted yield curve?
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.